本文選題：扶正化瘀膠囊 + 阿德福韋酯　； 參考：《中草藥》2017年18期

【摘要】：系統(tǒng)評(píng)價(jià)扶正化瘀膠囊聯(lián)合阿德福韋酯治療慢性乙型肝炎肝纖維化的療效和安全性。計(jì)算機(jī)檢索萬(wàn)方、中國(guó)知網(wǎng)、維普、中國(guó)生物醫(yī)學(xué)、Pub Med、Cochrane、Embase等數(shù)據(jù)庫(kù),搜集扶正化瘀膠囊聯(lián)合阿德福韋酯治療慢性乙型肝炎肝纖維化的隨機(jī)對(duì)照試驗(yàn)(RCT),檢索時(shí)間從建庫(kù)至2017年3月。由2位研究者獨(dú)立篩選文獻(xiàn)、提取資料、評(píng)價(jià)文獻(xiàn)質(zhì)量。采用Rev Man 5.3軟件對(duì)所提取的數(shù)據(jù)資料進(jìn)行Meta分析。共納入13項(xiàng)研究,1 400例研究對(duì)象。Meta分析結(jié)果顯示,與單用阿德福韋酯相比,扶正化瘀膠囊聯(lián)合阿德福韋酯不僅可以降低慢性乙型肝炎肝纖維化患者血清肝纖維化指標(biāo):HA[MD=-99.66,CI=-129.94~-69.37,P0.000 01]、LN[MD=-40.99,CI=-58.56~-23.41,P0.000 01]、PCIII[MD=-76.40,CI=-108.15~-44.66,P0.000 01]、IV-C[MD=-55.24,CI=-79.19~-31.29,P0.000 01];還能明顯改善肝功能指標(biāo):ALT[MD=-21.05,CI=-22.58~-19.52,P0.000 01]、AST[MD=-16.74,CI=-25.14~-8.33,P0.000 1]、TBIL[MD=-10.38,CI=-14.17~-6.59,P0.000 01]、ALB[MD=4.35,CI=-3.48~5.23,P0.000 01],改善B超影像學(xué)結(jié)果,且無(wú)明顯不良反應(yīng)。扶正化瘀膠囊聯(lián)合阿德福韋酯能顯著改善肝功能,降低肝纖維化指標(biāo),且不良反應(yīng)少,但尚需通過(guò)更多大樣本、高質(zhì)量的臨床試驗(yàn)進(jìn)一步驗(yàn)證其療效。
[Abstract]:To evaluate the efficacy and safety of Fuzheng Huayu capsule combined with adefovir in the treatment of chronic hepatitis B liver fibrosis. To search the databases of Wanfang, Zhiwang, Weipu, Pub Meden Cochraneto Embase and so on, a randomized controlled trial of Fuzheng Huayu capsule combined with adefovir in the treatment of chronic hepatitis B liver fibrosis was conducted. The retrieval time was from the establishment of the database to March 2017. Two researchers independently sifted the literature, extracted the data and evaluated the quality of the literature. The extracted data were analyzed by Meta using Rev Man 5.3 software. A meta-analysis of 1 400 subjects included in 13 studies showed that compared with adefovir alone, 鎵舵鍖栫榾鑳跺泭鑱斿悎闃垮痙紱忛煢閰笉浠呭彲浠ラ檷浣庢參鎬т箼鍨嬭倽鐐庤倽綰ょ淮鍖栨?zhèn)ｈ�呰娓呰倽綰ょ淮鍖栨寚鏍，

本文編號(hào)：1878192